Elcelyx Therapeutics is developing novel therapeutics based on Gut Sensory Modulation (GSM) science to address unmet needs in the pharmaceutical market. The company's lead proprietary product, metformin delayed-release (Metformin DR; also referred to as “NewMet”) has demonstrated clinical proof-of-concept for the treatment of type 2 diabetes and plans are to initiate a Phase 3 clinical trial later this year in the currently under-served moderate to severe renally‑impaired type 2 diabetes patient population.

Metformin DR is being developed to potentially address the needs of the metformin intolerant and renally contraindicated type 2 sub-populations. ADA and EASD guidelines suggest that metformin is the preferred first agent for all patients with type 2 diabetes if not contraindicated and if tolerated.  Metformin DR, by virtue of its unique delivery may have clinical utility in both populations.